Outlook Therapeutics (OTLK) Change in Account Payables (2015 - 2026)

Outlook Therapeutics (OTLK) has reported Change in Account Payables for 12 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables rose 223.25% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $4.9 million (up 28.53% YoY), while the FY2025 annual figure was $1.7 million, up 19.5% from the prior year.
• Change in Account Payables grew to $5.7 million in Q1 2026 per OTLK's latest filing, from -$2.9 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $5.7 million in Q1 2026 and bottomed at -$4.6 million in Q1 2025.
• Historically, Change in Account Payables has averaged $594220.5 across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2022 — Change in Account Payables surged 357.48% — and 2025, when it tumbled 1833.96%.
• Outlook Therapeutics' Change in Account Payables stood at $678394.0 in 2022, then sank by 556.11% to -$3.1 million in 2023, then soared by 236.51% to $4.2 million in 2024, then tumbled by 168.03% to -$2.9 million in 2025, then surged by 298.56% to $5.7 million in 2026.
• Business Quant data shows OTLK's Change in Account Payables at $5.7 million in Q1 2026, -$2.9 million in Q4 2025, and $30255.0 in Q3 2025.